Akụkọ - Ọgwụ ọrịa shuga nwere ike melite mgbaàmà ọrịa Parkinson

Ọgwụgwọ ọrịa shuga nwere ike melite mgbaàmà ọrịa Parkinson

Lixisenatide, onye na-anabata glucagon-dị ka peptide-1 agonist (GLP-1RA) maka ọgwụgwọ ọrịa shuga, na-ebelata dyskinesia na ndị ọrịa nwere ọrịa Parkinson n'oge, dịka nsonaazụ nke nnwale ụlọ ọgwụ 2 nke e bipụtara na New England Journal of Medicine. NEJM) na Eprel 4, 2024.

Ọmụmụ ihe a, nke ụlọ ọgwụ University nke Toulouse (France) duziri, wetara isiokwu 156, kewara otu n'etiti otu ndị na-ahụ maka ọgwụgwọ lixisenatide na otu placebo.Ndị nyocha ahụ tụlere mmetụta nke ọgwụ ahụ site na iji Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Nkebi nke atọ, yana akara dị elu n'ọkwa na-egosi nsogbu mmegharị ahụ ka njọ.Nsonaazụ gosiri na n'ime ọnwa 12, akara MDS-UPDRS nke III belatara site na 0.04 isi (na-egosi ntakịrị mmụba) na otu lixisenatide wee mụbaa site na isi 3.04 (na-egosi na ọrịa ahụ na-akawanye njọ) na placebo otu.

Otu akwụkwọ akụkọ NEJM dị ugbu a kwuru na, n'elu, data ndị a na-egosi na lixisenatide gbochiri kpamkpam nrịbawanye nke mgbaàmà ọrịa Parkinson n'ime ọnwa 12, mana nke a nwere ike ịbụ echiche nwere nchekwube.All MDS-UPDRS akpịrịkpa, gụnyere Nkebi nke Atọ, bụ akpịrịkpa agwakọta nke nwere ọtụtụ akụkụ, na imeziwanye n'otu akụkụ nwere ike igbochi mmebi na nke ọzọ.Na mgbakwunye, otu abụọ ikpe nwere ike irite uru naanị site na isonye na nnwale ụlọ ọgwụ.Agbanyeghị, ndịiche dị n'etiti otu nnwale abụọ ahụ yiri ka ọ bụ eziokwu, nsonaazụ ya na-akwado mmetụta lixisenatide na mgbaàmà ọrịa ọrịa Parkinson na usoro ọrịa nwere ike.

N'ihe banyere nchekwa, pasent 46 nke ndị a na-emeso lixisenatide nwere ọgbụgbọ na pasent 13 nwere ahụmahụ vomiting. Akwụkwọ akụkọ NEJM na-atụ aro na mmetụta nke mmetụta ndị ọzọ nwere ike igbochi iji lixisenatide eme ihe n'ọtụtụ ebe na ọgwụgwọ ọrịa Parkinson, ya mere nyocha ọzọ. Mbelata dose na ụzọ enyemaka ndị ọzọ ga-aba uru.

"N'ime ule a, ọdịiche dị na akara MDS-UPDRS dị ịrịba ama ma ọ dị ntakịrị mgbe ọnwa 12 gachara ọgwụgwọ ya na lixisenatide. Mkpa nchọpụta a abụghị n'ịdị ukwuu nke mgbanwe ahụ, kama n'ihe ọ na-egosi."Akwụkwọ akụkọ ahụ e kwuru n'elu na-ede, sị, "Ihe kachasị nchegbu maka ọtụtụ ndị na-arịa ọrịa Parkinson abụghị ọnọdụ ha ugbu a, kama egwu nke ọganihu ọrịa. Ọ bụrụ na lixisenatide na-eme ka ọnụ ọgụgụ MDS-UPDRS dịkwuo elu karịa ihe 3, mgbe ahụ, uru ọgwụgwọ ọgwụ ahụ nwere ike ịdị oke (n'ezie). N'aka nke ọzọ, ọ bụrụ na arụmọrụ lixisenatide na-agbakọta, na-abawanye akara site na isi 3 ọzọ kwa afọ n'ime oge 5 ruo 10 ma ọ bụ karịa, mgbe ahụ nke a nwere ike ịbụ ọgwụgwọ na-agbanwe agbanwe nzọụkwụ ọzọ bụ doro anya na-eduzi ule nke ogologo oge."

Onye France na-emepụta ọgwụ Sanofi (SNY.US), nke US Food and Drug Administration (FDA) kwadoro lixisenatide maka ọgwụgwọ ụdị ọrịa shuga 2 na 2016, na-eme ka ọ bụrụ GLP-1RA nke ise ka a na-ere ahịa n'ụwa niile. Site na nnwale ụlọ ọgwụ, ọ naghị arụ ọrụ n'ibelata glucose dị ka ndị otu ya liraglutide na Exendin-4, na ntinye ya n'ahịa US bịara karịa nke ha, na-eme ka o sie ike maka ngwaahịa a.Na 2023, ewepụrụ lixisenatide n'ahịa US.Sanofi na-akọwa na nke a bụ n'ihi azụmahịa kama okwu nchekwa ma ọ bụ ịdị irè na ọgwụ ahụ.

Ọrịa Parkinson bụ ọrịa neurodegenerative nke na-emekarị n'etiti ndị agadi na ndị toro eto, nke a kacha mara ya site na ịma jijiji izu ike, nkwụsi ike na mmegharị nwayọọ nwayọọ, na-enweghi ihe kpatara ya.Ka ọ dị ugbu a, isi ihe na-agwọ ọrịa ọrịa Parkinson bụ ọgwụgwọ nnọchi dopaminergic, nke na-arụ ọrụ nke ọma iji meziwanye mgbaàmà yana enweghị ihe akaebe doro anya nke na-emetụta ọganihu ọrịa.

Ọtụtụ nchọpụta gara aga achọpụtala na GLP-1 agonists na-anabata ya na-ebelata mbufụt nke ụbụrụ.Neuroinflammation na-eduga na mfu nke mkpụrụ ndụ ụbụrụ na-emepụta dopamine na-aga n'ihu, akụkụ bụ isi nke ọrịa ọrịa Parkinson.Otú ọ dị, ọ bụ nanị GLP-1 agonists receptor agonists nwere ohere na ụbụrụ dị irè na ọrịa Parkinson, na nso nso a semaglutide na liraglutide, bụ ndị a maara nke ọma maka mmetụta ha na-efunahụ ibu, egosighi ike ịgwọ ọrịa ọrịa Parkinson.

Na mbụ, nnwale nke otu ndị na-eme nchọpụta na Institute of Neurology na Mahadum London (UK) mere, chọpụtara na exenatide, nke dị ka lixisenatide, na-eme ka mgbaàmà ọrịa Parkinson dịkwuo mma.Nsonaazụ nke nnwale ahụ gosiri na na izu 60, ndị ọrịa na-agwọ ọrịa exenatide nwere mbelata 1-point na akara MDS-UPDRS ha, ebe ndị a na-emeso ya na placebo nwere nkwalite 2.1-point.Onye rụpụtara ya bụ Eli Lilly (LLY.US), nnukwu ụlọ ọrụ ọgwụ US, exenatide bụ agonist nnabata GLP-1 izizi n'ụwa, bụ nke ejirila ahịa ahụ kemgbe afọ ise.

Dị ka ọnụ ọgụgụ si kwuo, ọ dịkarịa ala isii GLP-1 agonists na-anabata ma ọ bụ na-anwale ugbu a maka ịdị irè ha n'ịgwọ ọrịa Parkinson.

Dị ka otu World Parkinson's Association si kwuo, enwere ndị ọrịa ọrịa Parkinson dị nde 5.7 ugbu a n'ụwa niile, yana ihe dị ka nde 2.7 na China.N'afọ 2030, China ga-enwe ọkara nke ọnụ ọgụgụ ndị ọrịa Parkinson n'ụwa.Ahịa ọgwụ ọrịa ọrịa Parkinson zuru ụwa ọnụ ga-ere ahịa ijeri RMB 38.2 na 2023 ma na-atụ anya iru RMB 61.24 ijeri na 2030, ka DResaerch (DIResaerch) siri kwuo.

Oge nzipu: Eprel-24-2024